Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 406,465 shares, a growth of 19.7% from the December 31st total of 339,482 shares. Currently, 5.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 60,252 shares, the short-interest ratio is presently 6.7 days. Based on an average daily trading volume, of 60,252 shares, the short-interest ratio is presently 6.7 days. Currently, 5.6% of the shares of the stock are sold short.

Institutional Trading of Cel-Sci

A number of large investors have recently added to or reduced their stakes in CVM. US Bancorp DE bought a new stake in shares of Cel-Sci during the 3rd quarter worth $80,000. Bank of America Corp DE boosted its position in shares of Cel-Sci by 2,188.2% in the 2nd quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after purchasing an additional 39,190 shares during the period. MAI Capital Management increased its stake in Cel-Sci by 18.4% in the 3rd quarter. MAI Capital Management now owns 76,861 shares of the company’s stock worth $707,000 after purchasing an additional 11,928 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Cel-Sci by 59.7% during the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after buying an additional 109,352 shares during the period. 12.08% of the stock is currently owned by institutional investors.

Cel-Sci Stock Performance

Shares of NYSEAMERICAN:CVM traded down $0.16 during trading on Tuesday, reaching $5.24. The company had a trading volume of 54,222 shares, compared to its average volume of 77,785. The firm’s fifty day moving average is $5.78 and its 200 day moving average is $7.65. The company has a current ratio of 2.26, a quick ratio of 2.20 and a debt-to-equity ratio of 0.36. Cel-Sci has a twelve month low of $1.98 and a twelve month high of $20.41.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.